A Trial Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

393

Participants

Timeline

Start Date

May 8, 2024

Primary Completion Date

May 1, 2025

Study Completion Date

May 8, 2025

Conditions

Adult Patients With Type 2 Diabetes

Interventions

DRUG

HR17031 injection

DRUG

insulin glargine

Trial Locations (1)

Shanghai Zhu Xianyi Memorial Hospital, Tianjin Medical University, Tianjin

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY